As AAV gene therapy of CHM is becoming a clinical reality with several ongoing studies (NCT01461213, NCT02407678, NCT02671539, NCT02553135, NCT02077361, NCT02341807), there is a need for reliable and sensitive in vitro assays to determine the biological activity of rAAV2/2-REP1. This evidence concerns the gene CHM and choroideremia.